目前根据病因可将肺高血压分为五大类。第一大类是肺动脉高压（PAH），主要包括特发性肺动脉高压（idiopathic pulmonary arterial hy pertension，IPAH）、结缔组织疾病、艾森曼格综合征（先天性心脏病）、肝脏疾病、HIV等相关PAH。第...目前根据病因可将肺高血压分为五大类。第一大类是肺动脉高压（PAH），主要包括特发性肺动脉高压（idiopathic pulmonary arterial hy pertension，IPAH）、结缔组织疾病、艾森曼格综合征（先天性心脏病）、肝脏疾病、HIV等相关PAH。第二大类是左心疾病包括瓣膜性心脏病、心肌病、缺血性心脏病等相关的肺高血压。第三大类是呼吸疾病或低氧相关的肺高血压。第四大类是由于机化血栓或栓子导致肺动脉闭塞引起的肺高血压。展开更多
Objective To investigate the current practice of pulmonary hypertension including current epidemiology, diagnosis and treatment. Data sources The review was based on data obtained from the published articles and guide...Objective To investigate the current practice of pulmonary hypertension including current epidemiology, diagnosis and treatment. Data sources The review was based on data obtained from the published articles and guidelines. Study selection Articles with high level of evidence or current best evidence in each issue were selected to be reviewed. Results Overall prevalence of pulmonary hypertension was 0.3% to 6% with left heart disease occupying the most proportion, followed by pulmonary disease, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. In diagnosis, a flow diagram of diagnosis of pulmonary hypertension, differential diagnosis of pulmonary hypertension and how to determine the severity of pulmonary hypertension are explained including recent development of magnetic resonance imaging and gene abnormality study on bone morphogenetic protein receptor ll. In treatment, newly- developed pulmonary vasodilators and the way to use them are shown to treat pulmonary hypertension. Conclusion Safer and more effective treatment algorithm and basic researches and clinical trials are warranted to be explored.展开更多
文摘目前根据病因可将肺高血压分为五大类。第一大类是肺动脉高压（PAH），主要包括特发性肺动脉高压（idiopathic pulmonary arterial hy pertension，IPAH）、结缔组织疾病、艾森曼格综合征（先天性心脏病）、肝脏疾病、HIV等相关PAH。第二大类是左心疾病包括瓣膜性心脏病、心肌病、缺血性心脏病等相关的肺高血压。第三大类是呼吸疾病或低氧相关的肺高血压。第四大类是由于机化血栓或栓子导致肺动脉闭塞引起的肺高血压。
文摘Objective To investigate the current practice of pulmonary hypertension including current epidemiology, diagnosis and treatment. Data sources The review was based on data obtained from the published articles and guidelines. Study selection Articles with high level of evidence or current best evidence in each issue were selected to be reviewed. Results Overall prevalence of pulmonary hypertension was 0.3% to 6% with left heart disease occupying the most proportion, followed by pulmonary disease, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. In diagnosis, a flow diagram of diagnosis of pulmonary hypertension, differential diagnosis of pulmonary hypertension and how to determine the severity of pulmonary hypertension are explained including recent development of magnetic resonance imaging and gene abnormality study on bone morphogenetic protein receptor ll. In treatment, newly- developed pulmonary vasodilators and the way to use them are shown to treat pulmonary hypertension. Conclusion Safer and more effective treatment algorithm and basic researches and clinical trials are warranted to be explored.
